Experienced in Measles

Dr. Julie S. Shepard

Pediatrics
7371 Brandt Pike, Suite C, 
Huber Heights, OH 
Experienced in Measles
7371 Brandt Pike, Suite C, 
Huber Heights, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Julie Shepard is a Pediatrics provider in Huber Heights, Ohio. Dr. Shepard is rated as an Experienced provider by MediFind in the treatment of Measles. Her top areas of expertise are Measles, Chickenpox, and Rubella.

Her clinical research consists of co-authoring 10 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 3 articles in the study of Measles.

Specialties
Pediatrics
Licenses
Pediatrics in OH
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

7371 Brandt Pike, Suite C, Huber Heights, OH 45424

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: August 03, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants
Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants
Enrollment Status: Completed
Publish Date: January 14, 2025
Intervention Type: Biological
Study Phase: Phase 3
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Lebrikizumab
Study Phase: Phase 3
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Drug
Study Phase: Phase 3
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 24, 2023
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder
A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder
Enrollment Status: Terminated
Publish Date: June 03, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Fixed-Dose, Efficacy, and Safety Study of SHP465 in Children Aged 6-12 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Fixed-Dose, Efficacy, and Safety Study of SHP465 in Children Aged 6-12 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
Enrollment Status: Completed
Publish Date: June 02, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Double Blind, Randomized, Sham Controlled Trial to Investigate the Effect of the CREON2000A on Asthma Control in Children With Mild to Moderate Persistent Asthma
A Double Blind, Randomized, Sham Controlled Trial to Investigate the Effect of the CREON2000A on Asthma Control in Children With Mild to Moderate Persistent Asthma
Enrollment Status: Completed
Publish Date: November 03, 2020
Intervention Type: Device
Study Phase: Not Applicable
Impact of Infant Formula on Caregiver-perceived Intolerance
Impact of Infant Formula on Caregiver-perceived Intolerance
Enrollment Status: Completed
Publish Date: June 09, 2020
Intervention Type: Other
Study Phase: Not Applicable
Acceptance Of A Partially-Hydrolyzed Infant Formula
Acceptance Of A Partially-Hydrolyzed Infant Formula
Enrollment Status: Completed
Publish Date: January 09, 2019
Intervention Type: Other
Study Phase: Not Applicable
Infant Formula GI Tolerance Evaluation
Infant Formula GI Tolerance Evaluation
Enrollment Status: Completed
Publish Date: May 23, 2018
Intervention Type: Other
Study Phase: Not Applicable
View 10 Less Clinical Trials

10 Total Publications

Clesrovimab for Prevention of RSV Disease in Healthy Infants.
Clesrovimab for Prevention of RSV Disease in Healthy Infants.
Journal: The New England journal of medicine
Published: September 17, 2025
Similar Doctors
Advanced in Measles
Dr. Rosemary A. Martoma
Pediatrics
Advanced in Measles
Dr. Rosemary A. Martoma
Pediatrics
4766 W Broad St, 
Columbus, OH 
 (52.2 miles away)
614-722-6200
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Rosemary Martoma is a Pediatrics provider in Columbus, Ohio. Dr. Martoma is rated as an Advanced provider by MediFind in the treatment of Measles. Her top area of expertise is Measles. Dr. Martoma is currently accepting new patients.

Advanced in Measles
Dr. Matthew C. Washam
Pediatric Infectious Disease | Infectious Disease | Pediatrics
Advanced in Measles
Dr. Matthew C. Washam
Pediatric Infectious Disease | Infectious Disease | Pediatrics
555 S 18th St, 
Columbus, OH 
 (60.2 miles away)
614-722-6200
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Matthew Washam is a Pediatric Infectious Disease specialist and an Infectious Disease provider in Columbus, Ohio. Dr. Washam is rated as an Experienced provider by MediFind in the treatment of Measles. His top areas of expertise are Measles, Multisystem Inflammatory Syndrome in Children (MIS-C), Parainfluenza, and Methicillin-Resistant Staphylococcus Aureus (MRSA). Dr. Washam is currently accepting new patients.

Experienced in Measles
Dr. Christopher P. Ouellette
Pediatric Infectious Disease | Infectious Disease | Pediatrics
Experienced in Measles
Dr. Christopher P. Ouellette
Pediatric Infectious Disease | Infectious Disease | Pediatrics

Pediatric Academic Association, Inc.

700 Children's Dr, 
Columbus, OH 
 (60.1 miles away)
614-722-4579
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Christopher Ouellette is a Pediatric Infectious Disease specialist and an Infectious Disease provider in Columbus, Ohio. Dr. Ouellette is rated as an Experienced provider by MediFind in the treatment of Measles. His top areas of expertise are Cytomegalovirus Infection, Congenital Cytomegalovirus, Acute Pulmonary Histoplasmosis, and Cytomegalic Inclusion Disease. Dr. Ouellette is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Shepard's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile